Recently, Scribe Therapeutics announced a cooperation agreement
with Sanofi.
Sanofi will use CRISPR genome editing technology developed by Scribe to engineer innovative NK cell therapies to fight tumors
.
According to the agreement, Sanofi will pay Scribe an advance payment of $25 million, as well as a milestone of
up to $1 billion based on development and commercialization progress.
It is understood that as early as September 27, Sanofi announced that it is cooperating with ScribeTherapeutics to use its CRISPR technology to develop cell therapy based on Natural Killer, an immune cell
with anti-cancer ability.
Industry analysts believe that Sanofi will use Scribe Therapeutics' CRISPR genome editing technology to improve and innovate NK cell therapy, which will be more effective in fighting tumors
.
In fact, in recent years, in the context of increasing changes in the pharmaceutical environment, Sanofi has been frequently initiating cooperation
in research and development in order to accelerate the improvement of competitiveness.
Since the beginning of this year, it has reached cooperation agreements
with many domestic and foreign pharmaceutical companies.
On October 4, for example, Sanofi and biotechnology company miReccure announced a $430 million research collaboration and licensing agreement that will drive the development
of similar antibody-RNA conjugates (ARCs) for the treatment of facial muscular atrophy (FSHD).
Under the terms of the transaction, miRecule granted Sanofi a worldwide exclusive intellectual property license
for FSHD therapies.
They will then collaborate on research until the primary drug candidate is selected
.
At that time, Sanofi will take over all new drug research as well as development and commercialization, and will pay miRecule an advance payment of $30 million and recent milestones
.
On August 5, Cinda Bio announced that it has reached a multi-project strategic cooperation and licensing agreement with Sanofi to cooperate in the development of two high-potential anti-tumor drugs SAR408701 (Tusamitamab Ravtansine; The clinical development and commercialization of anti-CEACAM5 antibody-drug conjugate) and SAR444245 (non-α-biased IL-2) in China, including exploring a series of clinical studies in combination with the PD-1 inhibitor Daboshu ® (Xindilizumab injection), with the aim of accelerating the development and market access of innovative therapies to benefit cancer patients in
China.
In addition, the two parties have also reached a share issuance agreement, and Sanofi will invest in Cinda Bio
by subscribing for shares.
In the future, if the two parties reach a new agreement, Sanofi can also re-subscribe for shares
in Cinda Biologics with a total value of 300 million euros.
On March 2, Tianyan Pharmaceutical announced that it has reached a cooperation agreement
with Sanofi with a down payment of US$17.
5 million and a profit of US$2.
5 billion.
Among them, Tianyan Pharmaceutical is responsible for the early development of the product, using its safety antibody SAFEbody technology to help Sanofi develop its new generation of monoclonal and bispecific antibodies of precision masking safety antibodies; Sanofi is responsible for further research and development and commercialization of the product in the
future.
.
.
.
.
.
.
It is worth mentioning that at present, under the frequent cooperation, Sanofi has begun to usher in the harvest
.
It is reported that on September 5 this year, Sanofi and Generative Element said that the drug they jointly developed Dupixent (dabitor, generic name: dupilumab) showed efficacy and safety
for up to two years in 365 children aged 6 to 11 with moderate to severe inflammatory asthma type 2.
In the same month, Beyfortus, a new drug released by Sanofi and AstraZeneca, was also recommended by the European Medicines Agency (EMA) Committee on Human Pharmaceutical Products (CHMP) for the prevention of syncytial virus
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize:"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];
